Best treatments for lung neoplasms

Understanding lung neoplasms

Lung cancer is cancer that starts in the lungs, most often in the cells that line the airways (bronchi). According to the National Cancer Institute (NCI) and MedlinePlus, there are two main types: non-small cell lung cancer, which is the most common, and small cell lung cancer. Early lung cancer often causes no symptoms. When symptoms do appear, they may include a cough that does not go away, chest pain, coughing up blood, shortness of breath, wheezing, hoarseness or a changing voice, fatigue, loss of appetite, and losing weight without trying. Lung cancer is sometimes first noticed on a chest x-ray done for another reason. To diagnose lung cancer and find out whether it has spread, clinicians may use imaging tests such as chest x-ray, CT, PET, MRI, and bone scans, along with sputum testing and a biopsy (for example, by bronchoscopy, needle biopsy, or mediastinoscopy) to examine lung tissue under a microscope. Determining how big the tumor is and how far it has spread is called staging, which helps guide treatment and follow-up. This is general information and is not medical advice.

Frequently asked

What treats lung neoplasms?

Our catalog lists 18 products that may treat lung neoplasms, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is imdelltra.

What is the best-rated treatment for lung neoplasms?

By our independent recall-safety rating — not an efficacy measure — imdelltra ranks highest among the products we list for lung neoplasms. Always consult a professional.

How are these treatments ranked?

By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.

What types of drugs treat lung neoplasms?

Treatments for lung neoplasms span FDA drug classes including alkylating drug, topoisomerase inhibitor, platinum-based drug, anthracycline topoisomerase inhibitor, kinase inhibitor. Compare every option side by side, ranked by independent rating, above.

Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.